Shanghai United Imaging Healthcare stock
688271.SSSHHShanghai United Imaging Healthcare Co., Ltd., HealthcareISIN CNE100005PN5
53Score 53 out of 100, Neutral
Price and trend
67 / 100
Price history
−18% in one yearThe chart shows daily closes over 4 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 1.0% above it.
Since December 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 20% below its 52-week high. Largest decline in 4 years: 57% (October 2022 to September 2024).
Chart figures for advanced users
- SMA 50$16.27
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$17.12
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.73
- The lowest closing price of the last twelve months.
- Resistance$21.72
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Shanghai United Imaging Healthcare Co., Ltd. belongs to the Medical (Specialties) industry (China) and, with a market value of $14.26B, is number 3 of 14 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.07B (up 34% year on year) and earnings of $280.23M (up 48.1%).
- For fiscal 2026, analysts expect on average revenue of $2.48B (up 19.8%) and adjusted earnings per share of $0.38 (up 23%).
Show more
- MEQIRI Score 53 out of 100 (Neutral): rank 352 of 714 in Healthcare, median 53.
- The P/E is 82.6 (Healthcare sector median 32.6, own median of recent years 69).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 19.2% a year since 2020, Healthcare sector median 12%.Growth 51
- High return on capitalReturn on invested capital 26.5% in fiscal 2025, Healthcare sector median 9.1%.Profitability 53
- Analysts expect strong earnings growthUp 24.8% a year through 2028 (estimates from 12 analysts).Growth 51
Weaknesses
- Richly valuedP/E 82.6, Healthcare sector median 32.6, own median 69.Valuation 13
- Negative free cash flowFree cash flow −$14.83M over the last 12 months.Fundamentals 43
- DilutionShare count up 18% since 2020.Capital allocation 58
Its standout strength is stability, while fundamentals and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 54 to 53.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
OvervaluedClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 34% on the prior year. Revenue has grown strongly since 2018, at around 31% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 47%, operating 14%, net 14%. Last 12 months: net 7%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 5 May 2027in 174 days
- Last reported
- 29 Oct 2026EPS reported $0.03 (expected $0.05)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.6% since 26 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.38−3.3%
- Revenue
- $2.48B−0.2%
- Earnings per share
- $0.48−3.6%
- Revenue
- $2.95B−0.6%
MEQIRI has stored the estimates since 26 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Shanghai United Imaging Healthcare
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 53
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next larger and next smaller companies by market value
- AlconALC.SW $34.65B62
- STERISSTE $24.89B70
- Sysmex6869.T $7.83B70
- Ypsomed HoldingYPSN.SW $6.56B76
- Medacta GroupMOVE.SW $2.64B58
- Eckert & ZieglerEUZ.DE $969.93M74
- QuidelOrthoQDEL $817.18M32
- Mesa LaboratoriesMLAB $782.43M58
ETFs that hold Shanghai United Imaging Healthcare
Held by 40 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| HSBC MSCI China A UCITS ETF USDH41K | 0.30% | 0.30% | €68.25M |
| Xtrackers Harvest CSI300 UCITS ETF 1DRQFI | 0.25% | 0.65% | €251.46M |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.25% | 0.65% | €10.8M |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.06% | 0.30% | €134.65M |
| WisdomTree Emerging Markets ex-State Owned Enterprises UCITS ETF AccumUSDXSOE | 0.05% | 0.32% | €17.98M |
| HSBC MSCI China UCITS ETFH4ZP | 0.04% | 0.28% | €865.21M |
| Franklin FTSE China UCITS ETFFLXC | 0.04% | 0.19% | €1.3B |
| Amundi MSCI Emerging Markets ESG Selection UCITS ETF DR (C)SADM | 0.02% | 0.18% | €1.02B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CN¥6.6707)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.